CRT Washington, D.C. February 23, 2010 Tim A. Fischell, M.D. FACC

Slides:



Advertisements
Similar presentations
M.Unverdorben; ACC March 2008 Martin Unverdorben Rotenburg/Fulda, Germany and Richmond, VA, USA Clinical Research Institute, Center for Cardiovascular.
Advertisements

IVUS Use during Left Main PCI improve Immediate and Long Term Outcome Where is the Evidence? E Murat Tuzcu, MD, FACC Professor of Medicine Vice Chairman.
W e m a k e i d e a s c o m e a l i v e 001IHP For internal use only Not only a peripheral stent available in Renal sizes...
CORONARY PRESSURE MEASURENT AND FRACTIONAL FLOW RESERVE
Chaim Lotan MD, Yaron Almagor MD, Karel Kuiper MD, M.J. Suttorp MD, William Wijns MD The SICTO Study CYPHER TM Sirolimus-eluting stent in Chronic Total.
When I Use IVUS Neal Uren MD FRCP Consultant Cardiologist Royal Infirmary Edinburgh.
LONG-TERM OUTCOMES OF PERCUTANEOUS CORONARY INTERVENTION FOR UNPROTECTED LEFT MAIN CORONARY ARTERY DISEASE: INITIAL CLINICAL EXPERIENCE. Graidis Ch. 1,
Range & Specifications CASE #1: 80% stenosis of the left renal artery located at the ostium of the vessel. HELIOS 6x13.
The First Affiliated Hospital of Harbin Medical University
Featuring Bifurcation Trans-Radial Approach Technical Issues Martial Hamon Caen, France Provisionnal T stenting With the Frontier stent Main Branch Balloon.
Philippe Généreux, MD for the Tryton Bifurcation Trial Investigators Columbia University Medical Center Cardiovascular Research Foundation New York City.
Date of download: 9/18/2016 Copyright © The American College of Cardiology. All rights reserved. From: Percutaneous Treatment of Protected and Unprotected.
Intravascular ultrasound (IVUS) in percutaneous coronary intervention – summary of key articles While angiography is routinely used for assessment of CAD,
Intravascular ultrasound (IVUS) in the treatment of long and diffuse lesions– summary of key articles Prepared by Radcliffe Cardiology 21 November2016.
November 9, 2015 February 20, 2017 Using real world evidence – industry perspective Pma indication expansion Melissa hasenbank, phd Sr. Clinical Research.
The Endocross Enabler-P: First in-Human Results
A new technique of IVUS guided CTO PCI
Adel Gamal, MD and Mohamed Saber, Msc
Ospedale San Raffaele, Milan, Italy
Regulatory Challenges for Bioabsorbable Stent Approval
Successful transdradial removal of a dislodged coronary stent
Transradial Intervention: Complex Case Review Yes, They Can Be Done!
New Stent Designs Applicable for Renal Intervention
Bifurcation Balloon & Stent Delivery System
Invasive Assessment of Coronary Artery Disease
Renal Artery Angioplasty and Stenting with Embolic Protection
Direct access of the SFA: step by step
A.B. Mehta, Ajit Desai, S.R. Handa, Nihar Mehta 
James P. Zidar, M.D., F.A.C.C., F.S.C.A.I
Understanding Stent Deformation
Regulatory Challenges for Bioasorbable Stent Approval
Guideliner related stent stripping
Clinical Presentation
(DES)+BVS +DCB for long diffuse LAD disease
EVAR Planning: Keys to Success
A Novel “Stent-On-A-Wire”Ultra Low Profile Stent Delivery System
Aorta Infrarenal Stenosis: BE, SE or Covered Stents? CRT 2012
Bioabsorbable DES and Biodegradable Polymers – FDA View
Acute and Mid-Term Outcomes of Coronary Stent Implantation for the Treatment of Unprotected Left Main Coronary Artery Disease Dr mahmoud ebrahimi Dr hosein.
Meruzhan Saghatelyan, MD, Interventional cardiologist
The Winking Saphenous Vein Graft: Acute Aorto-Vein Graft Anastomotic Torsional Kink causing Dynamic Systolic Compression Complicating Vein Graft PCI Dr.
A Fixed Guidewire Stent Delivery System
Renal Unit-Careggi University Hospital-Florence-Italy
ABSORB Japan: 3-year Clinical and Angiographic Results of a Randomized trial Evaluating the Absorb Bioresorbable Vascular Scaffold vs. Metallic Drug-eluting.
SFA Access for TASC D lesions.
The Tryton Bifurcation Trial:
Debate: What Does the Future Hold for the Treatment of Unprotected Left Main Disease? More PCI No More Routine Surgery Ron Waksman, MD, FACC Washington.
BVS Expand: First Results of Wide Clinical Applications
Complex PCI to CTO lesion in RCA with nightmares complications
The XIENCE V EXCEED Study
Subintimal Tracking and Reentry for CTO STAR Method
Stent Thrombosis Rates in Contemporary Clinical Practice: Insight from a Large Australian Multi-centre Registry BP Yan*, TJ Kiernan, SJ Duffy, DJ Clark,
OCT-Guided PCI What needs to be done to establish criteria?
MACE Trial Rationale, Study Design, and Current Status
Regulatory Considerations for Coronary Drug Coated Balloons – FDA View
Fractional Flow Reserve Workshop
Circ Cardiovasc Interv
Impact of calcium on procedural and clinical outcomes in lesions treated with bioresorbable vascular scaffolds - A prospective BRS registry study  Jiang.
Intraprocedural imaging: Thoracic aortography techniques, intravascular ultrasound, and special equipment  Rodney A. White, MD, Carlos E. Donayre, MD,
Impact of transrenal aortic endograft placement on endovascular graft repair of abdominal aortic aneurysms  Michael L. Marin, MD, Richard E. Parsons,
SIRIUS: A U.S. Multicenter, Randomized, Double-Blind Study of the SIRolImUS-Eluting Stent in De Novo Native Coronary Lesions Presented at TCT 2002.
Bifurcation Disease: Simulation Training Curriculum
Incidence and management of restenosis after treatment of unprotected left main disease with drug-eluting stents: 70 restenotic cases from a cohort of.
12-month clinical and 13-month angiographic outcomes from a randomized trial evaluating the Absorb Bioresorbable Vascular Scaffold vs. metallic drug-eluting.
Percutaneous balloon fenestration and stenting for life-threatening ischemic complications in patients with acute aortic dissection  Suzanne M. Slonim,
Technical aspects of repair of juxtarenal abdominal aortic aneurysms using the Zenith fenestrated endovascular stent graft  Gustavo S. Oderich, MD, Mateus.
Management of acute type B aortic dissection
Presented at TCT 2006.
ISAR-LEFT MAIN: A Randomized Clinical Trial on Drug-Eluting Stents for Unprotected Left Main Lesions J. Mehilli, MD Deutsches Herzzentrum Technische.
ISAR-LEFT MAIN: A Randomized Clinical Trial on Drug-Eluting Stents for Unprotected Left Main Lesions J. Mehilli, MD Deutsches Herzzentrum Technische.
Presentation transcript:

The “Ostial ProTM” Stent Positioning Device A Tool for Precise Aorto-Ostial Stent Placement CRT Washington, D.C. February 23, 2010 Tim A. Fischell, M.D. FACC Professor of Medicine, Michigan State University Director of Cardiovascular Research Borgess Medical Center Kalamazoo, Michigan

Rationale For Development of Ostial Stent Positioning System Anatomy of stent positioning at aorto-ostial location is very challenging. Angiographic landmarks via angiography are often ambiguous or misleading. This results in frequent mis-placement of stent: 1) too distal, either not recognized -> restenosis or requires additional (overlapped) stent ($$). 2) too proximal, protrudes into aorta so you may never be able to re-engage the vessel again (metal sticking out !)

Rationale For Development of Ostial Stent Positioning System Need for correct positioning is even more critical in new era of DES (cost and drug overlap issues). Ostial stent positioning device should be simple to use, nearly foolproof, provide positioning to ± 0.5 mm in all cases, and compatible with ~ all coronary and renal stents, all guiding catheters 6 Fr or larger. Market for device includes RCA and left main ostials, SVG aorto-ostials, renal, SMA, IMA, celiac & vertebral ostial lesions -> estimated worldwide market = > 290,000 cases in 2010.

A B Problems With Ostial Stent Placement A B IVUS of body of stent True RCA Ostium Restenosis 4 Months After Ostial RCA Stent Placement A Lumen at true ostium No stent placed there ! After Repeat Stenting 4.5 mm Bx Hepacoat B

Ostial ProTM Stent Positioning System in 6 Fr. Guide Ostial ProTM Cylinder Outside Guiding Catheter Ostial ProTM Being Withdrawn Into 6 Fr. Guiding Catheter Ostial ProTM Expanded Position at Tip of Guiding Catheter Ostial ProTM Expanded Position Simulation of Legs Against Aortic Wall

Ostial ProTM Stent Positioning System Stent Alignment Stent Deployment Stent Flaring “Conical Flaring”

Ostial Pro Device First U.S. Ostial Pro Positioning Case Calcified RCA Ostial Lesion (pre) After Stent) Long Axis IVUS Stent After Os Pro Position Calcified RCA Ostial Lesion (pre) After Stent Exactly at Ostium True RCA Ostium Proximal Stent edge

Ostial ProTM Stent Position in SVG Ostial ProTM Legs Deployed Stent Balloon Inflated Ostial ProTM Legs Deployed Pre-Deployed Stent Distal Ostial ProTM Legs Deployed SDS Positioned Final Angiogram SVG After Stent Deployed

Ostial ProTM Stent Position Unprotected LM Angiogram of LMCA Prior to Stenting IVUS at Ostium Angiogram of LMCA Post Stenting Long Axis IVUS of LMCA After Ostial ProTM Stent Positioning True Ostium False Ostium Proximal Stent Strut(s)

Ostial ProTM Stent Position in Renal Artery: St. John’s Hospital Ostial Renal Pre- Treatment Final Angiogram of Renal After Ostial ProTM Stent Positioning Proximal Flaring of Stent Edge Positioning of Stent With Ostial ProTM True Ostium Renal Artery Proximal Stent Strut(s) (Case by Tom Davis. M.D., St John’s Hospital, MI)

Results Ostial ProTM vs Control Cases Variable RCA Ostial Left Main Ostial SVG or LIMA Ostial Distal/ Proximal Miss Total Misses (> 1 mm) Ostial ProTM Cases N = 30 17 6 7 0/0 0/30 (0%) Control Cases 19 5 14/4 18/30 (60%)* * - p < 0.0001 vs. Ostial Pro Cases (Fisher Exact Test); Note - in 14 distal misses, 9 Rx. with POBA, 5 re-stented, with 2/5 second stents missed proximally. Overall 6/30 control cases could not be re-engaged with guiding catheter vs. 0/30 Ostial Pro cases (in press J Invasive Card, 2/09).

QCA Data Showing Stent “Flaring” at True Ostium * QCA Measurement (mean) mm Final Diameter At True Ostium MLD Baseline MLD After Stent Final RVD * - mean diameter at true ostium after Ostial Pro = 29±6% larger than stent MLD (p < 0.001)

FDA Regulatory Status Indications For Use 510 (k) Cleared Indications For Use “The Ostial Pro Stent Positioning System is intended for use in aorta-ostial procedures to introduce and position catheters, stents and other interventional devices within the coronary and peripheral vasculature. In addition, the Ostial Pro Stent Positioning System is intended to facilitate the alignment of interventional devices and function as an alignment tool.”

Ostial ProTM Positioning System Conclusions Ostial ProTM Positioning System The Ostial ProTM is a simple tool compatible with contemporary guiding catheters and stents to facilitate precise stent implantation in aorta-ostial lesions. This tool has been used with excellent results in the first in man clinical series. 0/30 misses with Ostial Pro vs. 18/30 missed ostia in historical controls (p<0.0001). The device is commercially available in U.S. with > 1,500 cases performed to date (coronary, renal, SMA,…). Manuscripts describing the first successful clinical cases have been published in Catheterization and Cardiovascular Interventions and J Inv Card.

Disclosures Co-inventor of Ostial Pro positioning device, licensed to Ostial Solutions, LLC. Co-founder of Ostial Solutions, LLC.

Ostial ProTM Stent Position Unprotected LM Ostial ProTM Legs Deployed Outside Ostium Angiogram of LMCA Prior to Stenting Angiogram of LMCA Post Stenting Ostial ProTM Legs Deployed On Aortic Wall True Ostium False Ostium Angiographic Site of Lesion

Ostial ProTM Stent Position in SVG Angiogram of RCA Prior to Stenting IVUS at Ostium Long Axis IVUS of RCA After Ostial ProTM Stent Positioning Angiogram of RCA Post Stenting True Ostium Case #4 Proximal Stent Strut(s)

Objective of Current Study We evaluated the stent positioning obtained with 30 consecutive, first in man, Ostial ProTM stent positioning cases for the treatment of coronary aorto-ostial stent placement, using IVUS (n=28) and QCA (n = 30), to assess the final result. The results with the Ostial ProTM stent positioning system were compared with consecutive historical control cases for treatement of coronary aorto-ostial lesions without the use of the positioning system (n = 30).